PE20081392A1 - Moleculas de enlace de lingo - Google Patents
Moleculas de enlace de lingoInfo
- Publication number
- PE20081392A1 PE20081392A1 PE2007001587A PE2007001587A PE20081392A1 PE 20081392 A1 PE20081392 A1 PE 20081392A1 PE 2007001587 A PE2007001587 A PE 2007001587A PE 2007001587 A PE2007001587 A PE 2007001587A PE 20081392 A1 PE20081392 A1 PE 20081392A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- fragment
- same
- binding molecules
- immunoglobulin
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
REFERIDA A UNA MOLECULA DE ENLACE QUE COMPRENDE LAS SECUENCIAS SEQ ID NO:1, SEQ ID NO:2 O SEQ ID NO:3. LA MOLECULA DE ENLACE COMPRENDE: a) UNA CADENA PESADA DE INMUNOGLOBULINA O UN FRAGMENTO DE LA MISMA, LA CUAL COMPRENDE: (i) UN DOMINIO VARIABLE QUE COMPRENDE LA SEC ID NO:5 O LA SEQ ID NO:7, Y (ii) LA PARTE CONSTANTE O UN FRAGMENTO DE LA MISMA, DE UNA CADENA PESADA HUMANA, Y b) UNA CADENA LIGERA DE INMUNOGLOBULINA O UN FRAGMENTO DE LA MISMA, LA CUAL COMPRENDE: (i) UN DOMINIO VARIABLE QUE COMPRENDE LA SEQ ID NO:4 O LA SEQ ID NO:6, Y (ii) LA PARTE CONSTANTE O UN FRAGMENTO DE LA MISMA, DE UNA CADENA LIGERA HUMANA. TAMBIEN ESTA REFERIDA A UN VECTOR DE EXPRESION, UN POLINUCLEOTIDO, UNA CELULA HUESPED AISLADA Y UNA COMPOSICION FARMACEUTICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124350 | 2006-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081392A1 true PE20081392A1 (es) | 2008-11-12 |
Family
ID=38325542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001587A PE20081392A1 (es) | 2006-11-17 | 2007-11-15 | Moleculas de enlace de lingo |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8299221B2 (es) |
| EP (2) | EP2395022A1 (es) |
| JP (2) | JP5647414B2 (es) |
| KR (1) | KR20090078353A (es) |
| CN (2) | CN101553506B (es) |
| AR (1) | AR063829A1 (es) |
| AT (1) | ATE502960T1 (es) |
| AU (1) | AU2007321817A1 (es) |
| BR (1) | BRPI0718406A2 (es) |
| CA (1) | CA2669181A1 (es) |
| CL (1) | CL2007003303A1 (es) |
| CO (1) | CO6180433A2 (es) |
| CR (1) | CR10756A (es) |
| DE (1) | DE602007013445D1 (es) |
| EC (1) | ECSP099332A (es) |
| ES (1) | ES2363622T3 (es) |
| GT (1) | GT200900121A (es) |
| IL (1) | IL198313A0 (es) |
| MA (1) | MA30965B1 (es) |
| MX (1) | MX2009005175A (es) |
| NO (1) | NO20092331L (es) |
| PE (1) | PE20081392A1 (es) |
| RU (1) | RU2009122514A (es) |
| TN (1) | TN2009000190A1 (es) |
| TW (1) | TW200831534A (es) |
| WO (1) | WO2008058736A1 (es) |
| ZA (1) | ZA200902409B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54160B1 (sr) | 2003-03-19 | 2015-12-31 | Biogen Idec Ma Inc. | Protein koji se vezuje za nogo receptor |
| BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| DK1904104T3 (da) | 2005-07-08 | 2013-11-11 | Biogen Idec Inc | SP35-antistoffer og anvendelser heraf |
| US20090175872A1 (en) * | 2005-12-02 | 2009-07-09 | Biogen Idec Ma Inc. | Treatment of Conditions Involving Demyelination |
| JP2009544703A (ja) | 2006-07-24 | 2009-12-17 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法 |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| EP2205071B1 (en) * | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| AU2009269099B2 (en) | 2008-07-09 | 2016-03-10 | Biogen Ma Inc. | Compositions comprising antibodies to LINGO or fragments thereof |
| AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| JP6294074B2 (ja) | 2010-04-27 | 2018-03-14 | エータイアー ファーマ， インコーポレイテッド | イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| EP2563382B1 (en) | 2010-04-27 | 2017-06-07 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases |
| AU2011248489B2 (en) | 2010-04-28 | 2016-10-06 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases |
| CN103118693B (zh) | 2010-04-29 | 2017-05-03 | Atyr 医药公司 | 与缬氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
| ES2668207T3 (es) | 2010-05-03 | 2018-05-17 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas |
| AU2011248227B2 (en) | 2010-05-03 | 2016-12-01 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| WO2011139988A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases |
| EP2566515B1 (en) | 2010-05-03 | 2017-08-02 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| CN103096909A (zh) | 2010-05-04 | 2013-05-08 | Atyr医药公司 | 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| US8945541B2 (en) | 2010-05-14 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| JP6027965B2 (ja) | 2010-05-17 | 2016-11-16 | エータイアー ファーマ， インコーポレイテッド | ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CN103096913B (zh) | 2010-05-27 | 2017-07-18 | Atyr 医药公司 | 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| US8962560B2 (en) | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
| EP2593126B1 (en) | 2010-07-12 | 2017-09-20 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| WO2012021247A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| KR102099730B1 (ko) | 2010-07-12 | 2020-04-16 | 에이티와이알 파마, 인코포레이티드 | 아스파르틸trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| JP5964304B2 (ja) | 2010-08-25 | 2016-08-03 | エータイアー ファーマ， インコーポレイテッド | チロシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| EP2624857B1 (en) | 2010-10-06 | 2017-08-02 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl trna synthetases |
| WO2013022982A2 (en) | 2011-08-09 | 2013-02-14 | Atyr Pharma, Inc. | Pegylated tyrosyl-trna synthetase polypeptides |
| WO2013086216A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Improved aspartyl-trna synthetases |
| US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
| EP2797959A4 (en) | 2011-12-29 | 2015-08-26 | Atyr Pharma Inc | ASPARTYL-tRNA synthetase FC CONJUGATES |
| EP2806948B1 (en) | 2012-01-27 | 2020-01-15 | New York University | Method for enhancing remyelination using gli1 inhibitors |
| KR102142161B1 (ko) * | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | 운동 뉴런 관련 병태 치료용 lingo-2 길항제 |
| CN114717206A (zh) | 2013-03-15 | 2022-07-08 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
| CA2973266A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| CN113079470B (zh) * | 2015-01-26 | 2025-02-18 | 苹果公司 | 提高水平和垂直定位准确性的设备和方法 |
| SG11201811704SA (en) * | 2016-07-13 | 2019-01-30 | Biogen Ma Inc | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| KR102414826B1 (ko) | 2020-06-18 | 2022-06-30 | 삼성전기주식회사 | 코일 부품 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308573D0 (en) | 1983-03-29 | 1983-05-05 | British Nuclear Fuels Ltd | Filament impregnating/coating |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| ES2085326T3 (es) | 1989-02-13 | 1996-06-01 | Schering Ag | Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1. |
| ES2352551T3 (es) * | 2003-03-19 | 2011-02-21 | Biogen Idec Ma Inc. | Proteína de unión a receptor nogo. |
| RS54160B1 (sr) | 2003-03-19 | 2015-12-31 | Biogen Idec Ma Inc. | Protein koji se vezuje za nogo receptor |
| US20050214288A1 (en) * | 2004-03-26 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies against Nogo receptor |
| BRPI0512500A (pt) * | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| DK1904104T3 (da) | 2005-07-08 | 2013-11-11 | Biogen Idec Inc | SP35-antistoffer og anvendelser heraf |
-
2007
- 2007-11-15 BR BRPI0718406-9A patent/BRPI0718406A2/pt not_active IP Right Cessation
- 2007-11-15 EP EP11151300A patent/EP2395022A1/en not_active Withdrawn
- 2007-11-15 DE DE602007013445T patent/DE602007013445D1/de active Active
- 2007-11-15 WO PCT/EP2007/009880 patent/WO2008058736A1/en active Application Filing
- 2007-11-15 AR ARP070105078A patent/AR063829A1/es not_active Application Discontinuation
- 2007-11-15 MX MX2009005175A patent/MX2009005175A/es not_active Application Discontinuation
- 2007-11-15 CA CA002669181A patent/CA2669181A1/en not_active Abandoned
- 2007-11-15 CN CN2007800415830A patent/CN101553506B/zh not_active Expired - Fee Related
- 2007-11-15 EP EP07846601A patent/EP2084190B1/en not_active Revoked
- 2007-11-15 ES ES07846601T patent/ES2363622T3/es active Active
- 2007-11-15 KR KR1020097009952A patent/KR20090078353A/ko not_active Ceased
- 2007-11-15 AU AU2007321817A patent/AU2007321817A1/en not_active Abandoned
- 2007-11-15 RU RU2009122514/10A patent/RU2009122514A/ru not_active Application Discontinuation
- 2007-11-15 PE PE2007001587A patent/PE20081392A1/es not_active Application Discontinuation
- 2007-11-15 AT AT07846601T patent/ATE502960T1/de not_active IP Right Cessation
- 2007-11-15 JP JP2009536654A patent/JP5647414B2/ja not_active Expired - Fee Related
- 2007-11-15 CN CN2013102559773A patent/CN103351437A/zh active Pending
- 2007-11-15 US US12/514,542 patent/US8299221B2/en not_active Expired - Fee Related
- 2007-11-16 TW TW096143597A patent/TW200831534A/zh unknown
- 2007-11-16 CL CL200703303A patent/CL2007003303A1/es unknown
-
2009
- 2009-04-07 ZA ZA200902409A patent/ZA200902409B/xx unknown
- 2009-04-23 IL IL198313A patent/IL198313A0/en unknown
- 2009-04-29 CR CR10756A patent/CR10756A/es not_active Application Discontinuation
- 2009-05-12 GT GT200900121A patent/GT200900121A/es unknown
- 2009-05-12 CO CO09048055A patent/CO6180433A2/es not_active Application Discontinuation
- 2009-05-15 EC EC2009009332A patent/ECSP099332A/es unknown
- 2009-05-15 TN TNP2009000190A patent/TN2009000190A1/fr unknown
- 2009-06-03 MA MA31944A patent/MA30965B1/fr unknown
- 2009-06-17 NO NO20092331A patent/NO20092331L/no not_active Application Discontinuation
-
2012
- 2012-09-14 US US13/616,226 patent/US20130071400A1/en not_active Abandoned
- 2012-10-04 JP JP2012222370A patent/JP2013056888A/ja active Pending
-
2013
- 2013-09-26 US US14/037,841 patent/US20140037639A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/280,933 patent/US20140255415A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081392A1 (es) | Moleculas de enlace de lingo | |
| CY1124802T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
| CY1119722T1 (el) | Δημιουργια και περιγραφη πληρως ανθρωπινων θεραπευτικων αντισωματων λαμβανομενων μεσω hucal gold ειδικων για ανθρωπινό cd38 | |
| CY1114904T1 (el) | Prlr-ειδικο αντισωμα και χρησεις αυτου | |
| CY1118120T1 (el) | Συνθεσεις βασιζομενες σε πεδιο ινωδονεκτινης τυπου iii, μεθοδοι και χρησεις αυτων | |
| RS51847B (en) | BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE | |
| RS53708B1 (en) | ANTIBODY MOLECULES SPECIFIC TO HUMAN IL-6 | |
| NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
| EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
| DE602004025101D1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| AR064456A1 (es) | Anticuerpos cd 44 | |
| EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
| RS52040B (en) | ANTI-EPCAM ANTIBODY AND ITS APPLICATIONS | |
| PE20120170A1 (es) | Variantes de union a anti-albumina de suero mejoradas | |
| MEP35408A (en) | Tweak binding antibodies | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| EA201001223A1 (ru) | Стабилизированные белковые композиции | |
| WO2007126799A3 (en) | Compositions and methods of use for antibodies of c-met | |
| EA200800355A1 (ru) | Нейтрализующие антитела человека против b7rp1 | |
| CY1115960T1 (el) | Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1 | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| CR11504A (es) | Deteccion mejorada de la expresion de mage-a | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |